Evaluation of in vivo targeting of andenocarcinomas with In-111-DTPA-B72.3-antibody under treatment with interferon gamma
- Univ. of Vienna (Austria); and others
The monoclonal antibody (mAb) In-111-DTPA-B72.3 directed against the tumor-associated glycoprotein (TAG)-72 has successfully been used for tumor diagnosis and staging, however, for evaluation of liver metastases the sensitivity is poor. Interferon gamma (IFNg) has been reported to increase TAG-72 expression on ascites tumor cells in patients with gastrointestinal adenocarcinomas. This study was undertaken to show a possible influence of IFNg on the diagnostic abilities of imunnoscintigraphy with In-111-DTPA-B72.3. We compared the in vivo targeting in 12 patients (9 males, 3 females, 59{plus_minus}16 years) under IFNg treatment (250 g daily s.c.) with a control group of 17 patients (10 males, 7 females, 66{plus_minus}10 years). In 5 patients (3 males, 2 females, 65{plus_minus}13 years) repeated scanning was performed before and during IFNg treatment. The patients suffered from advanced colorectal, pancreatic or gastric adenocarcinomas and underwent surgery and chemotherapy prior to scintigraphic investigations. In patients without IFNg, primary resp. residual tumors were imaged in 1 of 5 and liver metastases in 9 of 14 patients. In the IFNg-treated patients primary resp. residual tumors were visualized in 1 of 3 and Ever metastases in 8 of 9 patients (89%, vs 64% control group). Contrast of imaging for liver metastases was improved in 2 of 5 patients under treatment with IFNg while no difference in the visualization of primary resp. residual tumors could be realized under IFNg treatment. We conclude that in vivo targeting of TAG-72 with In-111-DTPA-B72.3 mAb may be increased in tumor patients under therapy with IFNg.
- OSTI ID:
- 197958
- Report Number(s):
- CONF-940605-; ISSN 0161-5505; TRN: 95:007029-0098
- Journal Information:
- Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
- Country of Publication:
- United States
- Language:
- English
Similar Records
Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy
Differences in biodistribution of indium-111-and iodine-131-labeled B72. 3 monoclonal antibodies in patients with colorectal cancer